ATH 04

Drug Profile

ATH 04

Alternative Names: AFFITOPE® AT04A+adjuvant; ATH-04

Latest Information Update: 03 Aug 2015

Price : $50

At a glance

  • Originator AFFiRiS
  • Class Antihyperlipidaemics; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action LDL receptor antagonists; PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Atherosclerosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Jul 2015 Phase-I clinical trials in Atherosclerosis in Austria (SC) (NCT02508896)
  • 20 Jun 2014 Preclinical trials in Atherosclerosis in Austria (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top